Indian Generics Case Worries Humanitarian Agencies
Pharmaceutical company Novartis is making final arguments to India's Supreme Court in the final stages of its six-year legal battle to overturn the Indian patent office's rejection of its drug Gleevec used for treating leukemia. The case has much broader consequences since much of the developing world depends on cheaper copies of expensive patented medicines that are manufactured in India. About $10 billion in Indian generics are exported annually. For example, Gleevec (or Glivec, as it is branded outside the US) can cost as much as $70,000 a year in the United States while the Indian generic versions cost ab...
Source: About.com Biotech Biomedical - December 31, 2012 Category: Biotechnology Source Type: news
Biotech Developments in 2012 and 2013
Out with the old and in with the new, as the saying goes. Of course, science doesn't really work that way. Each year builds on the previous work. However, the new year is typically a time to take stock, review the happenings of past year, and set expectations for the new one. In keeping with this tradition, I just posed Six Biotech Developments in 2012 and Predictions for Next Year which reviews some of the biotech highlights for 2012 and expected developments for the coming year....Read Full Post (Source: About.com Biotech Biomedical)
Source: About.com Biotech Biomedical - December 23, 2012 Category: Biotechnology Source Type: news
